All the news Showing 10 of 78 articles from: Triple therapyGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Triple combination cures most hepatitis C patients with prior DAA treatment failure Liz Highleyman / 02 May 2017 Almost all people with genotype 1 hepatitis C who were previously unsuccessfully treated with a course of interferon-free direct-acting antiviral therapy achieved sustained response when retreated with a three-drug combination ... NICE consults on draft guidance on the drug simeprevir (Olysio) for treating hepatitis C NICE / 25 September 2014 Paritaprevir (ABT-450)/ombitasvir/dasabuvir- List Of Upcoming and Recruiting Clinical Trials hepatitiscnewdrugs.blogspot.co.uk / 21 August 2014 88% of previous relapsers achieve hepatitis C cure with simeprevir-based triple therapy Keith Alcorn / 11 April 2014 Almost 90% of European patients who had relapsed after previous treatment with pegylated interferon and ribavirin were cured of hepatitis C after 24 weeks of treatment with the protease inhibitor simeprevir (Olysio) ... WHO recommends global use of newest hepatitis C drugs, urges price reductions Keith Alcorn / 09 April 2014 The World Health Organization has issued global treatment guidelines for hepatitis C, strongly recommending the use of the new direct-acting antivirals sofosbuvir (Sovaldi) with ribavirin for genotypes 1, 2, 3 and 4 or ... CHMP summary of opinion: simeprevir (Olysio) European Medicines Agency / 24 March 2014 Simeprevir receives positive CHMP opinion for the treatment of adults with chronic hepatitis C in the European Union Medivir press release / 21 March 2014 J&J-Medivir Drug for Hepatitis C Recommended by EU Regulator Bloomberg Businessweek / 21 March 2014 Faldaprevir plus interferon and ribavirin cures hepatitis C in most people with HIV/HCV co-infection Keith Alcorn / 21 March 2014 The hepatitis C protease inhibitor faldaprevir added to pegylated interferon and ribavirin cured hepatitis C in nearly three-quarters of people with genotype 1 hepatitis C virus (HCV) and HIV co-infection in ... New Phase III Data from Once-Daily Simeprevir Presented at the Conference of the Asian Pacific Association for the Study of the Liver (APASL) Medivir press release / 17 March 2014 ← First12345...8Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive